Turoctocog alfa
Pharmaceutical drug / From Wikipedia, the free encyclopedia
Dear Wikiwand AI, let's keep it short by simply answering these key questions:
Can you list the top facts and stats about NovoEight?
Summarize this article for a 10 year old
SHOW ALL QUESTIONS
Turoctocog alfa (trade name NovoEight) is a recombinant antihemophilic factor VIII used for the treatment of and prophylaxis of bleeding patients with haemophilia A. It is marketed by Novo Nordisk.[7][9][13] It was approved in the United States, the European Union, and Japan in 2013.[14][15][11][9]
Quick Facts Clinical data, Trade names ...
Clinical data | |
---|---|
Trade names | NovoEight, Esperoct |
Other names | recombinant antihemophilic factor |
AHFS/Drugs.com | Monograph |
License data | |
Pregnancy category |
|
Routes of administration | Intravenous (IV) |
ATC code | |
Legal status | |
Legal status | |
Identifiers | |
CAS Number | |
DrugBank | |
ChemSpider |
|
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C7480H11379N1999O2194S68 |
Molar mass | 166594.19 g·mol−1 |
Close